Is Viz.ai profitable in 2025?

Yes. Viz.ai announced on January 12, 2026 that its healthcare business reached profitability for the first time in 2025, while its Life Sciences pharma-partnership line doubled over the prior 18 months with six new pharma deals (vendor-claimed).

Who is Viz.ai's biggest competitor?

Aidoc is Viz.ai's most direct threat. Aidoc raised a Series E led by Goldman Sachs Alternatives in April 2026, received FDA Breakthrough Device Designation in September 2025 for its multi-pathology CARE1 foundation model, and has closed the accuracy gap in stroke/LVO detection.

Could AI replace Viz.ai's product?

Viz.ai's product is itself AI, so the risk is displacement by a better AI platform, not replacement by AI generally. Aidoc's multi-pathology CARE1 model, backed by FDA Breakthrough Designation in September 2025, is the named threat to Viz's per-indication approach.

Viz.ai is privately held and venture-backed, founded in 2016 by CEO Chris Mansi, MD. Investors from its priced rounds include Tiger Global Management, Insight Partners, Kleiner Perkins, GV, and Scale Ventures, with the last round in April 2022.

Has Viz.ai raised new funding recently?

No priced round has been publicly reported since Viz.ai's $100M Series D in April 2022, which valued the company at $1.2B. As of mid-2026 the company has not announced a follow-on priced raise.

What does Viz.ai actually do?

Viz.ai runs an AI-powered medical imaging detection and care-coordination platform with more than 50 FDA-cleared algorithms for conditions like stroke and subdural hemorrhage, deployed across nearly 2,000 hospitals as of January 2026, with real-time alerts to care teams.

AI companies and labs · United States

Viz.ai

viz.ai ↗

AI platform that flags strokes and other emergencies from medical scans.

Protection under test

Assessed 21 July 2026 · Evidence as of 21 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 21 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: Viz.ai's next priced funding round or disclosed down-round terms

The call

Viz.ai's hospital footprint and regulatory clearances hold steady while its valuation and funding timeline sit under open question.

Viz.ai builds artificial intelligence software that helps doctors spot problems in medical images like CT scans and X-rays, and hospitals use it in over 2,000 locations. The company has real advantages: it got permission from the government to use 50+ different detection tools, and insurance companies agreed to pay for some of its services, which takes years for new competitors to achieve. However, a rival company called Aidoc just raised major funding and built a new kind of AI system that can spot multiple problems at once instead of just one, and it is starting to close the gap in accuracy, which could make Viz.ai's lead disappear if hospitals switch to Aidoc's system to replace what Viz.ai does today.

Why

AI pressure: Aidoc (CARE1 foundation-model platform). Aidoc's CARE1 platform closed the stroke-detection gap and got FDA Breakthrough status, but has not displaced Viz.ai in named hospital accounts yet. Could AI do the core job? Only partly.

Bigger players: None apparent. No major cloud or imaging-hardware giant (GE, Philips, Siemens) has launched a competing platform at Viz.ai's clinical scale. Could a giant copy it? Probably.

What protects it. 50+ FDA-cleared algorithms, first CMS reimbursement status, and workflow lock-in across nearly 2,000 hospitals.

What would change this call

Aidoc's CARE1 platform winning system-wide hospital contracts that displace Viz.ai from stroke or cardiac workflows. Would show Aidoc converting its funding and FDA designation into real customer losses for Viz.ai.
Viz.ai completing a new priced funding round within the next year. An up-round near or above $1.2B would signal investor confidence; a down-round would confirm the valuation decline.
Viz.ai's Life Sciences (pharma partnership) revenue overtaking its core healthcare imaging revenue. Would show the company diversifying away from the segment where Aidoc competes most directly.

Key numbers

~2,000 hospitals running Viz.ai (2026-01-12)
Secondary market values Viz.ai ~$0.4B, down 67% (2026-06-29)
50+ FDA-cleared algorithms in use (2026-01-12)

Named risks

No new priced funding round since April 2022 Series D, leaving equity trajectory unclear. Severity: high
Aidoc's multi-pathology foundation-model platform could commoditize Viz's per-indication clearance moat. Severity: medium
Third-party headcount and revenue trackers disagree, obscuring real growth trajectory. Severity: low
Sector-wide AI-driven tech layoffs in 2026 could pressure hospital IT budgets and Viz's sales cycle. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Aidoc	gaining on	Series E led by Goldman Sachs Apr 2026; FDA Breakthrough Designation for CARE1 Sept 2025; closed LVO accuracy gap
RapidAI	contesting	Cited alongside Viz.ai as most validated stroke AI platform in Mar 2026 scoping review
GE HealthCare, Siemens Healthineers, Philips	contesting	Building scanner-tied radiology AI with 96/80/42 cleared tools respectively as of Jul 2026

Questions people ask

Is Viz.ai profitable in 2025?: Yes. Viz.ai announced on January 12, 2026 that its healthcare business reached profitability for the first time in 2025, while its Life Sciences pharma-partnership line doubled over the prior 18 months with six new pharma deals (vendor-claimed).
Who is Viz.ai's biggest competitor?: Aidoc is Viz.ai's most direct threat. Aidoc raised a Series E led by Goldman Sachs Alternatives in April 2026, received FDA Breakthrough Device Designation in September 2025 for its multi-pathology CARE1 foundation model, and has closed the accuracy gap in stroke/LVO detection.
Could AI replace Viz.ai's product?: Viz.ai's product is itself AI, so the risk is displacement by a better AI platform, not replacement by AI generally. Aidoc's multi-pathology CARE1 model, backed by FDA Breakthrough Designation in September 2025, is the named threat to Viz's per-indication approach.
Who owns Viz.ai?: Viz.ai is privately held and venture-backed, founded in 2016 by CEO Chris Mansi, MD. Investors from its priced rounds include Tiger Global Management, Insight Partners, Kleiner Perkins, GV, and Scale Ventures, with the last round in April 2022.
Has Viz.ai raised new funding recently?: No priced round has been publicly reported since Viz.ai's $100M Series D in April 2022, which valued the company at $1.2B. As of mid-2026 the company has not announced a follow-on priced raise.
What does Viz.ai actually do?: Viz.ai runs an AI-powered medical imaging detection and care-coordination platform with more than 50 FDA-cleared algorithms for conditions like stroke and subdural hemorrhage, deployed across nearly 2,000 hospitals as of January 2026, with real-time alerts to care teams.

Timeline

2026-04Aidoc closes Series E led by Goldman Sachs Alternatives
2026-01-12Viz.ai announces 2025 healthcare-business profitability and Life Sciences growth
2025-10-20Viz.ai launches Viz Assist, a multimodal AI agent platform
2025-09Aidoc receives FDA Breakthrough Device Designation for CARE1 platform
2025-06-13FDA 510(k) clearance for Viz Subdural Plus
2025-06-02Viz.ai announces multi-year Novartis oncology alliance
2025-05-28Viz.ai launches Viz Oncology Suite
2022-04-07Viz.ai raises $100M Series D at $1.2B valuation

Revision history

21 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Anthropic Stability AI Darktrace